## Jack L Arbiser

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5649459/publications.pdf

Version: 2024-02-01

225 papers 10,604 citations

53 h-index 92 g-index

230 all docs

230 docs citations

times ranked

230

14848 citing authors

#	Article	IF	CITATIONS
1	Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer. Cell Biology and Toxicology, 2023, 39, 1873-1896.	5.3	8
2	Aggravation of pulmonary fibrosis after knocking down the Aryl hydrocarbon receptor in the Insulinâ€like growth factor 1 receptor pathway. British Journal of Pharmacology, 2022, , .	5.4	4
3	Introduction of Mutant GNAQ into Endothelial Cells Induces a Vascular Malformation Phenotype with Therapeutic Response to Imatinib. Cancers, 2022, 14, 413.	3.7	6
4	Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo. Antioxidants, 2022, 11, 798.	5.1	1
5	Targeting aberrant replication and DNA repair events for treating breast cancers. Communications Biology, 2022, 5, .	4.4	1
6	Honokiol Bis-Dichloroacetate Is a Selective Allosteric Inhibitor of the Mitochondrial Chaperone TRAP1. Antioxidants and Redox Signaling, 2021, 34, 505-516.	5.4	26
7	Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo. Cancers, 2021, 13, 1220.	3.7	8
8	Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis. Cancers, 2021, 13, 1515.	3.7	7
9	Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia. Antioxidants, 2021, 10, 956.	5.1	5
10	Claisened Hexafluoro Inhibits Metastatic Spreading of Amoeboid Melanoma Cells. Cancers, 2021, 13, 3551.	3.7	2
11	Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB. Npj Breast Cancer, 2021, 7, 105.	5.2	12
12	Successful treatment of palmoplantar psoriasis with chemical peeling and gentian violet. JAAD Case Reports, 2021, 17, 28-30.	0.8	2
13	TH2 sensitization in the skinâ€gutâ€brain axis: How earlyâ€life Th2â€mediated inflammation may negatively perpetuate developmental and psychologic abnormalities. Pediatric Dermatology, 2021, 38, 1032-1039.	0.9	11
14	Mitochondrial Metabolism in Melanoma. Cells, 2021, 10, 3197.	4.1	11
15	Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-Î <sup>2</sup> 1/SMAD Signaling and Autophagy in Hepatic Stellate Cells. International Journal of Molecular Sciences, 2021, 22, 13354.	4.1	9
16	Evaluation of a First-in-Class Proteasome Inhibitor in Patients With Moderate to Severe Rosacea. Journal of Drugs in Dermatology, 2021, 20, 660-664.	0.8	3
17	Angiofibroma stimulation in a transgender person receiving gender-affirming testosterone. JAAD Case Reports, 2020, 6, 1101-1103.	0.8	O
18	Tris DBA ameliorates IgA nephropathy by blunting the activating signal of NLRP3 inflammasome through SIRT1―and SIRT3â€mediated autophagy induction. Journal of Cellular and Molecular Medicine, 2020, 24, 13609-13622.	3.6	17

#	Article	IF	Citations
19	Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab. JAAD Case Reports, 2020, 6, 761-765.	0.8	3
20	Tris DBA Ameliorates Accelerated and Severe Lupus Nephritis in Mice by Activating Regulatory T Cells and Autophagy and Inhibiting the NLRP3 Inflammasome. Journal of Immunology, 2020, 204, 1448-1461.	0.8	18
21	Establishment of a Temperature-Sensitive Model of Oncogene-Induced Senescence in Angiosarcoma Cells. Cancers, 2020, 12, 395.	3.7	3
22	Overcoming acquired resistance of EGFRâ€mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. Molecular Oncology, 2020, 14, 882-895.	4.6	26
23	Inhibitors of cytoskeletal dynamics in malignant mesothelioma. Oncotarget, 2020, 11, 4637-4647.	1.8	0
24	Propranolol exhibits activity against hemangiomas independent of beta blockade. Npj Precision Oncology, 2019, 3, 27.	5.4	32
25	Topical Application of Cinnamaldehyde Promotes Faster Healing of Skin Wounds Infected with Pseudomonas aeruginosa. Molecules, 2019, 24, 1627.	3.8	33
26	Palladium based nanoparticles for the treatment of advanced melanoma. Scientific Reports, 2019, 9, 3255.	3.3	18
27	Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and $\hat{l}^2$ -catenin pathways. Cancer Letters, 2019, 442, 113-125.	7.2	33
28	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 2019, 125, 18-44.	4.1	29
29	Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma <i>in vivo</i> . Oncotarget, 2019, 10, 4424-4436.	1.8	7
30	Diablo: A Double-Edged Sword inÂCancer?. Molecular Therapy, 2018, 26, 678-679.	8.2	1
31	ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response. Free Radical Biology and Medicine, 2018, 123, 39-52.	2.9	19
32	Salivary levels of angiopoietinâ€2 in infants with infantile haemangiomas treated with and without systemic propranolol. Experimental Dermatology, 2018, 27, 636-640.	2.9	4
33	Honokiol is a FOXM1 antagonist. Cell Death and Disease, 2018, 9, 84.	6.3	42
34	Targeting the Plasticity of Psoriasis. Journal of Investigative Dermatology, 2018, 138, 734-736.	0.7	5
35	Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. Molecular Cancer Therapeutics, 2018, 17, 204-214.	4.1	18
36	Regression of diffuse Bâ€cell lymphoma of the leg with intralesional gentian violet. Experimental Dermatology, 2018, 27, 93-95.	2.9	5

#	Article	lF	CITATIONS
37	Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. Clinical Cancer Research, 2018, 24, 858-869.	7.0	19
38	Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair. Science, 2018, 362, .	12.6	318
39	Antioxidants: Positive or Negative Actors?. Biomolecules, 2018, 8, 124.	4.0	150
40	Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2518-2527.	2.4	33
41	Double Jeopardy: The Rubber Ball Bounces Twice. Journal of Investigative Dermatology, 2017, 137, 15-17.	0.7	2
42	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metabolism, 2017, 25, 358-373.	16.2	109
43	Honokiol protects skin cells against inflammation, collagenolysis, apoptosis, and senescence caused by cigarette smoke damage. International Journal of Dermatology, 2017, 56, 754-761.	1.0	22
44	Peroxisome proliferatorâ€activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target. EMBO Molecular Medicine, 2017, 9, 508-530.	6.9	11
45	HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers. Journal of Biological Chemistry, 2017, 292, 10142-10152.	3.4	28
46	Targeting the duality of cancer. Npj Precision Oncology, 2017, 1, .	5.4	39
47	Activation of Protein Kinase C Îμ in Merkel Cell Polyomavirus–Induced Merkel Cell Carcinoma. JAMA Dermatology, 2017, 153, 931.	4.1	3
48	Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition. Journal of Biological Chemistry, 2017, 292, 11727-11739.	3.4	59
49	Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis. Scientific Reports, 2017, 7, 11198.	3.3	14
50	Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone. JAMA Dermatology, 2017, 153, 1018.	4.1	52
51	Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. Scientific Reports, 2017, 7, 4447.	3.3	22
52	Treatment of extensive erythema multiforme with topical gentian violet. Experimental Dermatology, 2017, 26, 431-432.	2.9	4
53	Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget, 2017, 8, 34082-34098.	1.8	137
54	Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies. Molecules, 2016, 21, 995.	3.8	5

#	Article	IF	CITATIONS
55	Factors Influencing Prescription Drug Costs in the United States. JAMA - Journal of the American Medical Association, 2016, 316, 2430.	7.4	O
56	Use of Polyphenolic Compounds in Dermatologic Oncology. American Journal of Clinical Dermatology, 2016, 17, 369-385.	6.7	21
57	Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. Leukemia and Lymphoma, 2016, 57, 2409-2416.	1.3	12
58	Inhibition of <i>FoxM1</i> -Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis. Clinical Cancer Research, 2016, 22, 3524-3536.	7.0	46
59	Enhanced Clearance of Pseudomonas aeruginosa by Peroxisome Proliferator-Activated Receptor Gamma. Infection and Immunity, 2016, 84, 1975-1985.	2.2	31
60	Down-Regulation of SOX2 Underlies the Inhibitory Effects of the Triphenylmethane Gentian Violet on Melanoma Cell Self-Renewal and Survival. Journal of Investigative Dermatology, 2016, 136, 2059-2069.	0.7	28
61	Tuberculosis verrucosa cutis lesions exhibit a greater microvessel count than lupus vulgaris lesions. Experimental Dermatology, 2016, 25, 479-480.	2.9	3
62	Improvement of "En Coup de Sabre―Morphea and Associated Headaches With Botulinum Toxin Injections. Dermatologic Surgery, 2016, 42, 1216-1219.	0.8	5
63	Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect. Journal of Investigative Dermatology, 2016, 136, 564-566.	0.7	3
64	Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma. Leukemia and Lymphoma, 2016, 57, 1677-1686.	1.3	20
65	Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis. Journal of Drug Targeting, 2016, 24, 503-507.	4.4	9
66	Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Oncotarget, 2016, 7, 51569-51580.	1.8	17
67	Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget, 2016, 7, 51651-51664.	1.8	12
68	SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget, 2016, 7, 69321-69336.	1.8	91
69	Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma <i>in vivo</i> . Oncotarget, 2016, 7, 12857-12868.	1.8	32
70	Gentian Violet: Bench-to-Bedside Research That Lowers Healthcare Costs. Skinmed, 2016, 14, 91-2.	0.0	0
71	Solenopsin A and analogs exhibit ceramide-like biological activity. Vascular Cell, 2015, 7, 5.	0.2	18
72	NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2121-2126.	7.1	41

#	Article	IF	Citations
73	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular Cell, 2015, 59, 345-358.	9.7	125
74	Efficacy of Rapamycin in Tuberous Sclerosis–Associated Hypopigmented Macules. JAMA Dermatology, 2015, 151, 703.	4.1	2
75	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	9.6	220
76	Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells. Microvascular Research, 2015, 97, 55-64.	2.5	19
77	Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1- $\hat{l}^2$ -catenin signaling axis in a microRNA-34a dependent manner. Oncotarget, 2015, 6, 16396-16410.	1.8	50
78	Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer. Oncotarget, 2015, 6, 29947-29962.	1.8	49
79	Imipramine Blue Sensitively and Selectively Targets FLT3 and c-Kit Mutant Acute Myeloid Leukemia. Blood, 2015, 126, 3688-3688.	1.4	0
80	Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma. Blood, 2015, 126, 2978-2978.	1.4	0
81	PHIPing Out: A Genetic Basis for Tumor Ulceration. Journal of Investigative Dermatology, 2014, 134, 600-602.	0.7	2
82	Honokiol inhibits epithelialâ€"mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/Eâ€cadherin axis. Molecular Oncology, 2014, 8, 565-580.	4.6	85
83	Current approaches to the treatment of metastatic brain tumours. Nature Reviews Clinical Oncology, 2014, 11, 203-222.	27.6	233
84	Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate, 2014, 74, 408-420.	2.3	24
85	The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Medicinal Chemistry, 2014, 6, 1413-1422.	2.3	70
86	Gentian violet induces wtp53 transactivation in cancer cells. International Journal of Oncology, 2014, 44, 1084-1090.	3.3	13
87	Honokiol Enhances Paclitaxel Efficacy in Multi-Drug Resistant Human Cancer Model through the Induction of Apoptosis. PLoS ONE, 2014, 9, e86369.	2.5	36
88	The novel Aryl hydrocarbon receptor inhibitor biseugenol inhibits gastric tumor growth and peritoneal dissemination. Oncotarget, 2014, 5, 7788-7804.	1.8	32
89	In Vivo Gram Staining of Tinea Versicolor. JAMA Dermatology, 2013, 149, 991.	4.1	2
90	The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Letters, 2013, 338, 292-299.	7.2	29

#	Article	IF	Citations
91	Reductions in Funding for Medical Research. JAMA - Journal of the American Medical Association, 2013, 310, 855.	7.4	O
92	Gentian Violet: a 19th century drug reâ€emerges in the 21st century. Experimental Dermatology, 2013, 22, 775-780.	2.9	108
93	Identifying new small molecule anti-invasive compounds for glioma treatment. Cell Cycle, 2013, 12, 2200-2209.	2.6	21
94	Triphenylmethane Derivatives Have High In Vitro and In Vivo Activity against the Main Causative Agents of Cutaneous Leishmaniasis. PLoS ONE, 2013, 8, e51864.	2.5	7
95	Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors. Current Pharmaceutical Design, 2013, 19, 4701-4713.	1.9	5
96	Anti-Invasive Adjuvant Therapy with Imipramine Blue Enhances Chemotherapeutic Efficacy Against Glioma. Science Translational Medicine, 2012, 4, 127ra36.	12.4	102
97	NHERF-2 silences the silencers. Blood, 2012, 119, 4582-4584.	1.4	0
98	Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases. Journal of the American Academy of Dermatology, 2012, 67, e81-e83.	1.2	31
99	Peroxiredoxin 3 Is a Redox-Dependent Target of Thiostrepton in Malignant Mesothelioma Cells. PLoS ONE, 2012, 7, e39404.	2.5	51
100	Antimetastatic activity of honokiol in osteosarcoma. Cancer, 2012, 118, 2117-2127.	4.1	44
101	Targeting NADPH oxidases for the treatment of cancer and inflammation. Cellular and Molecular Life Sciences, 2012, 69, 2435-2442.	5.4	74
102	Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the î"RG mouse model of tuberous sclerosis complex. Neurobiology of Disease, 2012, 45, 1101-1110.	4.4	72
103	Peroxisome proliferation–associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nature Medicine, 2011, 17, 1121-1127.	30.7	239
104	The Impact of Ionization States of Matrix Metalloproteinase Inhibitors on Docking-Based Inhibitor Design. ACS Medicinal Chemistry Letters, 2011, 2, 455-460.	2.8	9
105	Effectiveness of Gentian Violet and Similar Products Commonly Used to Treat Pyodermas.  Dermatologic Clinics, 2011, 29, 69-73.	1.7	24
106	A Key Role for NOX4 in Epithelial Cell Death During Development of Lung Fibrosis. Antioxidants and Redox Signaling, 2011, 15, 607-619.	5.4	249
107	Novel antiangiogenic agents in dermatology. Archives of Biochemistry and Biophysics, 2011, 508, 222-226.	3.0	15
108	High level expression of angiopoietin-2 in human abscesses. Journal of the American Academy of Dermatology, 2011, 64, 200-201.	1.2	2

#	Article	IF	CITATIONS
109	Targeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARα Mediated Mechanism. PLoS ONE, 2011, 6, e14665.	2.5	128
110	Honokiol stimulates osteoblastogenesis by suppressing NF- $\hat{l}^{\text{P}}\text{B}$ activation. International Journal of Molecular Medicine, 2011, 28, 1049-53.	4.0	19
111	Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes. Free Radical Biology and Medicine, 2011, 50, 811-820.	2.9	54
112	Forty-Year Journey of Angiogenesis Translational Research. Science Translational Medicine, 2011, 3, 114rv3.	12.4	181
113	Fumarate Esters as Angiogenesis Inhibitors: Key to Action in Psoriasis?. Journal of Investigative Dermatology, 2011, 131, 1189-1191.	0.7	27
114	Fisetin: A Natural Fist against Melanoma?. Journal of Investigative Dermatology, 2011, 131, 1187-1189.	0.7	5
115	TRIS (DIBENZYLIDENEACETONE) Dipalladium a Small-Molecule Palladium Complex Is Effective in the Induction of Apoptosis for B-Chronic Lymphocytic Leukemia B-Cells. Blood, 2011, 118, 2851-2851.	1.4	1
116	Pro-Apoptotic Activity of Honokiol Analogues in B-Cell Lymphoid Malignancies. Blood, 2011, 118, 1663-1663.	1.4	18
117	EC-specific chemotaxis receptor: a double-edged sword. Blood, 2010, 115, 4328-4329.	1.4	O
118	Enhanced MCPâ€1 release by keloid CD14+ cells augments fibroblast proliferation: role of MCPâ€1 and Akt pathway in keloids. Experimental Dermatology, 2010, 19, e142-50.	2.9	34
119	Translating Cyclooxygenase Signaling in Patch Heterozygote Mice into a Randomized Clinical Trial in Basal Cell Carcinoma. Cancer Prevention Research, 2010, 3, 4-7.	1.5	6
120	Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: Possible role of phospho-70-ribosomal-S6 kinase. Journal of the American Academy of Dermatology, 2010, 62, 343-345.	1.2	38
121	A nonsteroidal alternative to impetiginized eczema in the emergency room. Journal of the American Academy of Dermatology, 2010, 63, 537-539.	1.2	11
122	Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors. Clinical Cancer Research, 2010, 16, 2571-2579.	7.0	95
123	Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. Journal of Clinical Investigation, 2009, 119, 2359-65.	8.2	103
124	Secreted Frizzle-Related Protein 2 Stimulates Angiogenesis via a Calcineurin/NFAT Signaling Pathway. Cancer Research, 2009, 69, 4621-4628.	0.9	104
125	Melanomas Reveal Their Nakedness. Archives of Dermatology, 2009, 145, 587-8.	1.4	0
126	Tuberous Sclerosis Complex Suppression in Cerebellar Development and Medulloblastoma: Separate Regulation of Mammalian Target of Rapamycin Activity and p27Kip1 Localization. Cancer Research, 2009, 69, 7224-7234.	0.9	37

#	Article	IF	CITATIONS
127	Unexpected Autocrine Role of Vascular Endothelial Growth Factor in Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2009, 129, 538-540.	0.7	1
128	Efficacy of topical application of eosin for ulcerated hemangiomas. Journal of the American Academy of Dermatology, 2009, 60, 350-351.	1.2	37
129	Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. Journal of the American Academy of Dermatology, 2009, 60, 758-766.	1.2	32
130	Disseminated pyoderma gangrenosum: Role for vascular endothelial growth factor and hypoxia inducible factor-2. Journal of the American Academy of Dermatology, 2009, 61, 730-732.	1.2	8
131	Gentian violet is safe. Journal of the American Academy of Dermatology, 2009, 61, 359.	1.2	18
132	Honokiol, a Multifunctional Antiangiogenic and Antitumor Agent. Antioxidants and Redox Signaling, 2009, 11, 1139-1148.	5.4	274
133	The hunting of the Snrk. Blood, 2009, 113, 983-984.	1.4	11
134	Prox-1 Promotes Invasion of Kaposiform Hemangioendotheliomas. Journal of Investigative Dermatology, 2008, 128, 2798-2806.	0.7	47
135	Shb Gene Knockdown Increases the Susceptibility of SVR Endothelial Tumor Cells to Apoptotic Stimuli In Vitro and In Vivo. Journal of Investigative Dermatology, 2008, 128, 710-716.	0.7	15
136	Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochemical Pharmacology, 2008, 76, 589-596.	4.4	114
137	Targeted therapy of oral hairy leukoplakia with gentian violet. Journal of the American Academy of Dermatology, 2008, 58, 711-712.	1.2	37
138	Immunosuppression may be present within condyloma acuminata. Journal of the American Academy of Dermatology, 2008, 59, 967-974.	1.2	25
139	Honokiol Suppresses Survival Signals Mediated by Ras-Dependent Phospholipase D Activity in Human Cancer Cells. Clinical Cancer Research, 2008, 14, 4267-4274.	7.0	76
140	Epidermal Vascular Endothelial Growth Factor Production Is Required for Permeability Barrier Homeostasis, Dermal Angiogenesis, and the Development of Epidermal Hyperplasia. American Journal of Pathology, 2008, 173, 689-699.	3.8	90
141	Application of Angiogenesis to Clinical Dermatology. Advances in Dermatology, 2008, 24, 89-103.	2.0	15
142	A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9959-9964.	7.1	86
143	Solenopsin A, a Venom Alkaloid from the Fire Ant <i>Solenopsis invicta,</i> Inhibits Quorumâ€Sensing Signaling in <i>Pseudomonas aeruginosa</i> Iournal of Infectious Diseases, 2008, 198, 1198-1201.	4.0	66
144	Efficacy of Rapamycin in Scleroderma: A Case Study. Lymphatic Research and Biology, 2008, 6, 217-219.	1.1	25

#	Article	IF	Citations
145	Tris (Dibenzylideneacetone) Dipalladium, a <i>N</i> -Myristoyltransferase-1 Inhibitor, Is Effective against Melanoma Growth <i>In vitro</i> and <i>In vivo</i> . Clinical Cancer Research, 2008, 14, 5743-5748.	7.0	56
146	The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis. Molecular Cancer Therapeutics, 2008, 7, 2212-2223.	4.1	47
147	Imipramine Blue, a Tricyclic Compound and An Inhibitor of NADPH Oxidase Induces G2/M Cell Cycle Arrest Followed by Apoptosis in Multiple Myeloma Cells and in Leukemia Cells. Blood, 2008, 112, 5170-5170.	1.4	0
148	Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma. Cancer Research, 2007, 67, 1502-1512.	0.9	80
149	Angiogenesis in Cutaneous Lesions of Leprosy. Archives of Dermatology, 2007, 143, 1527-9.	1.4	11
150	AKT1 Overexpression in Endothelial Cells Leads to the Development of Cutaneous Vascular Malformations In Vivo. Archives of Dermatology, 2007, 143, 504-6.	1.4	56
151	Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood, 2007, 109, 560-565.	1.4	96
152	Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors. Expert Review of Anti-Infective Therapy, 2007, 5, 573-579.	4.4	29
153	Honokiol, a Natural Plant Product, Inhibits Inflammatory Signals and Alleviates Inflammatory Arthritis. Journal of Immunology, 2007, 179, 753-763.	0.8	108
154	Mammalian Target of Rapamycin (mTOR) is Activated in Cutaneous Vascular Malformations <i>in Vivo</i> . Lymphatic Research and Biology, 2007, 5, 233-236.	1.1	53
155	Expression of the Neural Stem Cell Markers NG2 and L1 in Human Angiomyolipoma: Are Angiomyolipomas Neoplasms of Stem Cells?. Molecular Medicine, 2007, 13, 160-165.	4.4	35
156	Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4428-4431.	2.2	63
157	Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. Journal of Clinical Investigation, 2007, 117, 719-729.	8.2	246
158	Why targeted therapy hasn't worked in advanced cancer. Journal of Clinical Investigation, 2007, 117, 2762-2765.	8.2	18
159	Facile Purification of Honokiol and Its Antiviral and Cytotoxic Properties. Journal of Medicinal Chemistry, 2006, 49, 3426-3427.	6.4	51
160	Presence of p16 hypermethylation and Epstein–Barr virus infection in transplant-associated hematolymphoid neoplasm of the skin. Journal of the American Academy of Dermatology, 2006, 55, 794-798.	1.2	20
161	Wilms Tumor 1 Expression Present in Most Melanomas but Nearly Absent in Nevi. Archives of Dermatology, 2006, 142, 1031-4.	1.4	17
162	Carbazole Is a Naturally Occurring Inhibitor of Angiogenesis and Inflammation Isolated from Antipsoriatic Coal Tar. Journal of Investigative Dermatology, 2006, 126, 1396-1402.	0.7	60

#	Article	IF	CITATIONS
163	Pharmacologic Blockade of Angiopoietin-2 Is Efficacious against Model Hemangiomas in Mice. Journal of Investigative Dermatology, 2006, 126, 2316-2322.	0.7	108
164	The Duality of Angiogenesis: Implications for Therapy of Human Disease. Journal of Investigative Dermatology, 2006, 126, 2160-2166.	0.7	20
165	Honokiol Potentiates Apoptosis, Suppresses Osteoclastogenesis, and Inhibits Invasion through Modulation of Nuclear Factor-κB Activation Pathway. Molecular Cancer Research, 2006, 4, 621-633.	3.4	128
166	Expression of Wilms Tumor 1 Gene Distinguishes Vascular Malformations From Proliferative Endothelial Lesions. Archives of Dermatology, 2005, 141, 1297-300.	1.4	90
167	gli-1 Oncogene Is Highly Expressed in Granulomatous Skin Disorders, Including Sarcoidosis, Granuloma Annulare, and Necrobiosis Lipoidica Diabeticorum. Archives of Dermatology, 2005, 141, 259-62.	1.4	30
168	PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12. Blood, 2005, 105, 1606-1613.	1.4	26
169	Synthesis and biological evaluation of aromatic enones related to curcumin. Bioorganic and Medicinal Chemistry, 2005, 13, 4007-4013.	3.0	126
170	Implications of Epstein–Barr Virus (EBV)-Induced Carcinogenesis on Cutaneous Inflammation and Carcinogenesis: Evidence of Recurring Patterns of Angiogenesis and Signal Transduction. Journal of Investigative Dermatology, 2005, 124, xi-xii.	0.7	7
171	Naturally Occurring Proteasome Inhibitors from Mate Tea (Ilex paraguayensis) Serve as Models for Topical Proteasome Inhibitors. Journal of Investigative Dermatology, 2005, 125, 207-212.	0.7	31
172	Combination Therapy of Doxycycline and Topical Tacrolimus for Venous Ulcers. Archives of Dermatology, 2005, 141, 1476-7.	1.4	12
173	Transgenic Expression of Dominant Negative Tuberin through a Strong Constitutive Promoter Results in a Tissue-specific Tuberous Sclerosis Phenotype in the Skin and Brain. Journal of Biological Chemistry, 2005, 280, 5870-5874.	3.4	33
174	Malignant Transformation of Human Cells by Constitutive Expression of Platelet-derived Growth Factor-BB. Journal of Biological Chemistry, 2005, 280, 13936-13943.	3.4	30
175	Reactive oxygen signaling and MAPK activation distinguish Epstein–Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 175-179.	7.1	142
176	Genital Dermatology AtlasEdwardsL.: Genital Dermatology Atlas. Philadelphia: Lippincott Williams & Wilkins2004. 320 pages Journal of Urology, 2005, 174, 1506-1507.	0.4	0
177	A Cyclosporine-Sensitive Psoriasis-Like Disease Produced in Tie2 Transgenic Mice. American Journal of Pathology, 2005, 166, 843-855.	3.8	86
178	Involvement of p53 and p16 Tumor Suppressor Genes in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2004, 123, 788-790.	0.7	40
179	Angiomotin expression promotes hemangioendothelioma invasion. Oncogene, 2004, 23, 1469-1473.	5.9	45
180	Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms. Seminars in Cancer Biology, 2004, 14, 81-91.	9.6	41

#	Article	IF	CITATIONS
181	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Can Induce Apoptosis in Subsets of Premalignant Cells. American Journal of Pathology, 2004, 165, 1613-1620.	3.8	14
182	Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. Journal of the American Academy of Dermatology, 2004, 50, 850-853.	1.2	99
183	Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma Blood, 2004, 104, 1488-1488.	1.4	0
184	The Natural Product Honokiol Induces Caspase-Dependent Apoptosis in Chronic Lymphocytic Leukmemia (CLL) Cells Blood, 2004, 104, 4777-4777.	1.4	0
185	Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 115-117.	2.2	107
186	Reversing the Angiogenic Switch with Photodynamic Therapy. Journal of Investigative Dermatology, 2003, 121, xi-xii.	0.7	0
187	Activation of B-raf in Non-Malignant Nevi Predicts a Novel Tumor Suppressor Gene in Melanoma (MAP) Tj ETQq1 1	0.78431 0.7	4 rgBT /Ove
188	Infectious Angiogenesis. American Journal of Pathology, 2003, 163, 1321-1327.	3.8	61
189	Regulation of endothelial cell differentiation and transformation by H-Ras. Experimental Cell Research, 2003, 291, 189-200.	2.6	7
190	Cutaneous lesions of secondary syphilis are highly angiogenic. Journal of the American Academy of Dermatology, 2003, 48, 878-881.	1.2	21
191	Molecular Pathogenesis of Vascular Anomalies: Classification into Three Categories Based upon Clinical and Biochemical Characteristics. Lymphatic Research and Biology, 2003, 1, 267-281.	1.1	43
192	Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesis in Vitro and Tumor Growth in Vivo. Journal of Biological Chemistry, 2003, 278, 35501-35507.	3.4	314
193	Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling. Journal of Biological Chemistry, 2003, 278, 9790-9795.	3.4	110
194	Weight Lossâ€Induced Calciphylaxis: Potential Role of Matrix Metalloproteinases. Journal of Dermatology, 2003, 30, 915-919.	1.2	28
195	Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clinical Cancer Research, 2003, 9, 3469-75.	7.0	29
196	Phosphorylation by Mitogen-activated Protein Kinase Mediates the Hypoxia-induced Turnover of the TAL1/SCL Transcription Factor in Endothelial Cells. Journal of Biological Chemistry, 2002, 277, 18365-18372.	3.4	26
197	Functional Tyrosine Kinase Inhibitor Profiling. American Journal of Pathology, 2002, 161, 781-786.	3.8	25
198	Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 715-720.	7.1	434

#	Article	IF	Citations
199	Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. Journal of the American Academy of Dermatology, 2002, 46, 376-380.	1.2	72
200	Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(lnk4a) and activation of MAP kinase. Molecular Medicine, 2002, $8$ , $1$ - $8$ .	4.4	52
201	SVR angiosarcomas can be rejected by CD4 costimulation dependent and CD8 costimulation independent pathways. Molecular Medicine, 2002, 8, 551-8.	4.4	6
202	Mitogen-actived protein kinase activation is an early event in melanoma progression. Clinical Cancer Research, 2002, 8, 3728-33.	7.0	205
203	The Generation and Characterization of a Cell Line Derived from a Sporadic Renal Angiomyolipoma. American Journal of Pathology, 2001, 159, 483-491.	3.8	37
204	Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: Implications for biologic behavior and response to therapy. Journal of the American Academy of Dermatology, 2001, 44, 193-197.	1.2	39
205	Diffuse dermal angiomatosis of the breast: Response to isotretinoin. Journal of the American Academy of Dermatology, 2001, 45, 462-465.	1.2	53
206	Microphthalmia transcription factor immunohistochemistry: A useful diagnostic marker in the diagnosis and detection of cutaneous melanoma, sentinel lymph node metastases, and extracutaneous melanocytic neoplasms. Journal of the American Academy of Dermatology, 2001, 45, 414-419.	1.2	34
207	Are keloids really "gli-loids�: High-level expression of gli-1 oncogene in keloids. Journal of the American Academy of Dermatology, 2001, 45, 707-711.	1.2	50
208	Neuroendocrine Lung Tumors: Grade Correlates with Proliferation but not Angiogenesis. Modern Pathology, 2001, 14, 1195-1199.	5 <b>.</b> 5	48
209	VEGF and its Receptors are Expressed in a Pediatric Angiosarcoma in a Patient with Aicardi's Syndrome. Journal of Investigative Dermatology, 2000, 114, 1209-1210.	0.7	29
210	Regulation of Angiogenesis and Tumorigenesis by Signal Transduction Cascades: Lessons from Benign and Malignant Endothelial Tumors. Journal of Investigative Dermatology Symposium Proceedings, 2000, 5, 79-82.	0.8	18
211	Inhibition of MAP Kinase Kinase Causes Morphological Reversion and Dissociation between Soft Agar Growth and in Vivo Tumorigenesis in Angiosarcoma Cells. American Journal of Pathology, 2000, 157, 1937-1945.	3.8	42
212	Overexpression of VEGF 121 in Immortalized Endothelial Cells Causes Conversion to Slowly Growing Angiosarcoma and High Level Expression of the VEGF Receptors VEGFR-1 and VEGFR-2 in Vivo. American Journal of Pathology, 2000, 156, 1469-1476.	3.8	113
213	Corticotropin-Releasing Hormone Stimulates Angiogenesis and Epithelial Tumor Growth in the Skin. Journal of Investigative Dermatology, 1999, 113, 838-842.	0.7	49
214	The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. Journal of the American Academy of Dermatology, 1999, 40, 925-929.	1.2	42
215	Isolation of Mouse Stromal Cells Associated with a Human Tumor Using Differential Diphtheria Toxin Sensitivity. American Journal of Pathology, 1999, 155, 723-729.	3.8	33
216	p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene, 1998, 17, 819-824.	5.9	53

#	Article	lF	CITATIONS
217	Analysis of vascularity of human neurofibromas. Journal of the American Academy of Dermatology, 1998, 38, 950-954.	1.2	47
218	Effects of Thallium Ion on Cellular Components of the Skin. Journal of Dermatology, 1997, 24, 147-155.	1.2	5
219	Angiogenesis and the skin: A primer. Journal of the American Academy of Dermatology, 1996, 34, 486-497.	1.2	85
220	Black tattoo reaction: The peacock's tale. Journal of the American Academy of Dermatology, 1996, 35, 477-479.	1.2	44
221	Genetic immunodeficiencies: Cutaneous manifestations and recent progress. Journal of the American Academy of Dermatology, 1995, 33, 82-89.	1.2	23
222	Clofazimine: A review of its medical uses and mechanisms of action. Journal of the American Academy of Dermatology, 1995, 32, 241-247.	1.2	172
223	Phorbol ester induced rapid attachment and spreading of melanoma cells and the role of extracellular matrix proteins. International Journal of Cancer, 1994, 57, 894-900.	5.1	21
224	Species-specific placental corticotropin releasing hormone messenger RNA and peptide expression. Molecular and Cellular Endocrinology, 1989, 62, 337-341.	3.2	84
225	Simple, inexpensive procedure for the large-scale production of alkyl quinones. Journal of Organic Chemistry, 1983, 48, 2932-2933.	3.2	37